For HIV-1 treatment in HTE* adults

If their regimen fails,
we'll be there

A first-in-class treatment with a novel mechanism of action1,2

For HIV-1 treatmentin HTE* adults

If their regimen fails,
we'll be there

A first-in-class
treatment with a novel
mechanism of action1,2

INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.

*Heavily treatment-experienced.

Sign Up for our next webinar

Read more »
edge of yesterday sub hero image
edge of yesterday sub hero image

Listen to Edge of Yesterday:

A Podcast Series by ViiV Healthcare

Read more »

"My name is James. I’m a heavily treatment-experienced person living with HIV. I have a great deal of hopefulness. I just have to remain positive.”

James, living with HIV.

Compensated by ViiV Healthcare.

DISCOVER RUKOBIA

BRIGHTE CLINICAL
TRIAL

Learn about the efficacy and safety of RUKOBIA in BRIGHTE

Read more »
pill icon

DOSING AND DRUG
INTERACTIONS

Learn about administering RUKOBIA

Read more »

ViiV MEDICAL
INFORMATION

View our medical information library if you have a question about RUKOBIA

Read more »

A DEEPER LOOK AT RUKOBIA

RISKS & SIDE EFFECTS

Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation

Read more »
MOA

A NOVEL
MECHANISM
OF ACTION

Learn what makes RUKOBIA a first-in-class HIV-1 attachment inhibitor1,2

Read more »

EDUCATIONAL RESOURCES

View educational library for RUKOBIA, including videos and a downloadable resource

Read more »

References:

  1. Data on file, ViiV Healthcare.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated June 3, 2021. Accessed June 7, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf

FSTWCNT210017